Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level

Kouji Izumi, Wen Jye Lin, Hiroshi Miyamoto, Chiung Kuei Huang, Aerken Maolake, Yasuhide Kitagawa, Yoshifumi Kadono, Hiroyuki Konaka, Atsushi Mizokami, Mikio Namiki

Research output: Contribution to journalArticle

Abstract

Purpose: Prostate-specific antigen (PSA) is a useful biomarker of prostate cancer (PCa). High-risk localized PCa is defined using T stage, Gleason score (GS), and PSA. However, PSA level defining high-risk PCa is at most 20 ng/mL. In PCa patients with high PSA, it is unclear whether PSA itself can be a prognostic factor. Methods: Of 642 patients who were diagnosed as PCa, 90 patients with PSA > 100 ng/mL were retrospectively analyzed. Patients were divided into three groups according to PSA level: very high (>1,000 ng/mL), moderately high (200-1,000 ng/mL), and slightly high (100-200 ng/mL). Results: There were no significant differences in overall survival or PCa-specific survival (PCaSS) among the three groups. Regardless of PSA level, high M stage and GS significantly reduced PCaSS. When the risk classification was made using M stage and GS (high risk = M1 and GS ≥ 9, low risk = M0 and GS < 9, and intermediate risk = others), PCaSS was significantly different among high-, intermediate-, and low-risk groups with 5-year survival rates of 58.2, 80.6, and 100 %, respectively. Although there were no differences in treatment performed during the castration-resistant stage, patients undergoing alternative anti-androgen and zoledronic acid treatment had better PCaSS after being castration-resistant. Conclusions: As PSA could not be a prognostic factor in PCa patients with high PSA > 100 ng/mL, the novel risk classification using M stage and GS may help clinicians to predict PCaSS and to plan follow-up schedules after diagnosis.

Original languageEnglish (US)
Pages (from-to)1413-1419
Number of pages7
JournalJournal of Cancer Research and Clinical Oncology
Volume140
Issue number8
DOIs
StatePublished - Aug 2014

Keywords

  • Castration-resistant prostate cancer
  • Gleason score
  • Prostate cancer
  • Prostate-specific antigen
  • TNM classification

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level'. Together they form a unique fingerprint.

  • Cite this

    Izumi, K., Lin, W. J., Miyamoto, H., Huang, C. K., Maolake, A., Kitagawa, Y., Kadono, Y., Konaka, H., Mizokami, A., & Namiki, M. (2014). Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level. Journal of Cancer Research and Clinical Oncology, 140(8), 1413-1419. https://doi.org/10.1007/s00432-014-1681-8